The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials

Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II type 1 receptors. It is an effective and well-tolerated once-daily antihypertensive agent, with a tolerability profile similar to placebo. A recent series of large-scale clinical trials have shown the benefits of valsartan in disease states beyond hypertension. Based on the results of the Val-HeFT (Valsartan in Heart Failure Trial) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) studies, valsartan is indicated for use in patients with heart failure and in patients post-myocardial infarction. Recently, in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, valsartan was no more cardioprotective than calcium channel blockers, but was shown to reduce the risk of developing new-onset diabetes in hypertensive patients at high risk of cardiac events compared with calcium antagonist treatment. In diabetic patients with microalbuminuria, valsartan has been shown to have benefits beyond those attributable to blood pressure lowering alone.

[1]  L. Tavazzi,et al.  Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. , 2005, Journal of cardiac failure.

[2]  I. Balaguer-Vintró,et al.  The electrocardiogram in mitral stenosis before and after commissurotomy. , 1955, American heart journal.

[3]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[4]  Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol , 1997, European Journal of Clinical Pharmacology.

[5]  F. Frech,et al.  Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting , 2003, Journal of managed care pharmacy : JMCP.

[6]  J. Neutel,et al.  Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. , 2000, Clinical therapeutics.

[7]  S. Kjeldsen,et al.  Never mind the quality, feel the width – ALLHAT revisited , 2004, Blood pressure.

[8]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[9]  J. Mallion,et al.  Valsartan/Hydrochlorothiazide is Effective in Hypertensive Patients Inadequately Controlled by Valsartan Monotherapy , 2003, Blood pressure. Supplement.

[10]  P. Palatini,et al.  Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. , 2004, Clinical therapeutics.

[11]  W. Hall,et al.  Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.

[12]  Y. Lacourciére,et al.  Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. , 2005, Clinical therapeutics.

[13]  R. Schmieder.  Mechanisms for the clinical benefits of angiotensin II receptor blockers. , 2005, American journal of hypertension.

[14]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[15]  M. de Gasparo,et al.  Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects , 1997, European Journal of Clinical Pharmacology.

[16]  Hongjie Zheng,et al.  LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF VALSARTAN : RESULTS FROM ONE AND TWO YEAR TRIALS , 1998 .

[17]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[18]  R. Carretta,et al.  Pulse Pressure Responses in Patients Treated with Valsartan and Hydrochlorothiazide Combination Therapy , 2003, The Journal of international medical research.

[19]  P. Palatini,et al.  A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. , 2003, Clinical therapeutics.

[20]  L. Ruilope,et al.  AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. , 1999, Hypertension.

[21]  J. Cohn,et al.  Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). , 2004, American heart journal.

[22]  M. Pfeffer,et al.  Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). , 2005, American heart journal.

[23]  P. Rolan,et al.  Pharmacokinetics of valsartan in patients with liver disease , 1997, Clinical pharmacology and therapeutics.

[24]  L. Hansson.  ‘WHY DON'T YOU DO AS I TELL YOU?’ COMPLIANCE AND ANTIHYPERTENSIVE REGIMENS , 2002, International journal of clinical practice.

[25]  D. Faulds,et al.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. , 1992, Drugs.

[26]  J. Cohn,et al.  Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. , 1999, Circulation.

[27]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[28]  M. de Gasparo,et al.  Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  K. Goa,et al.  Valsartan , 2012, Drugs.

[30]  M. Weir,et al.  Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. , 2001, American journal of hypertension.

[31]  L. Ruilope,et al.  Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. , 2005, Clinical therapeutics.

[32]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[33]  A. Mueck,et al.  Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. , 1999, International journal of clinical pharmacology and therapeutics.

[34]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[35]  J. Levine,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril , 1997, Journal of Human Hypertension.

[36]  J. Cohn,et al.  Effect of Valsartan on hospitalization: results from Val-HeFT. , 2003, Journal of cardiac failure.

[37]  R. Fogari,et al.  Addressing Those Two That Go Together: The Angiotensin II Receptors and their Role in Blood-flow Regulation , 2001, Blood pressure.

[38]  G. Mcinnes.  Hypertension control – an old song resung , 2004, Blood pressure.

[39]  A. Racine‐Poon,et al.  PHARMACOKINETICS AND DISPOSITION , 1998 .

[40]  S. Kjeldsen,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ , 2004 .

[41]  S. Tretli,et al.  Blood Pressure Levels in Treated Hypertensive Patients in General Practice in Norway , 2001, Blood pressure.

[42]  H. Parving,et al.  Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? , 2002, Circulation.

[43]  J. Hradec,et al.  Valsartan and atenolol in patients with severe essential hypertension , 1998, Journal of Human Hypertension.

[44]  N. Hollenberg,et al.  Literature alert , 2002 .

[45]  P. Verdecchia,et al.  Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. , 2004, Clinical therapeutics.

[46]  L. Wilton,et al.  The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England , 2002, Journal of Human Hypertension.

[47]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.